Drug intelligence / Profile preview

KI 1124

Development stage: Preclinical
Lead developer: Kuhnil Pharmaceutical
Modality: Small Molecules

Overview

KI 1124 is an investigational drug candidate currently in the preclinical research stage, developed by the South Korean company Kuhnil Pharma. It is being evaluated for the management of hyperlipidemia and diabetes. While specific pharmacological details such as its molecular target and modality have not been publicly disclosed, the project is part of Kuhnil Pharma's metabolic disease pipeline. The drug is currently undergoing early-stage research to establish its safety and efficacy profile for these metabolic indications.

Other names: Atorvastatin/Metformin FDC

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)ND1 (Mitochondrial electron transport chain complex I)AMPK (Adenosine monophosphate–activated protein kinase)

Beyond the preview

Go deeper on KI 1124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KI 1124.

Explore the full profile